Reliability and validity of the post COVID-19 condition stigma questionnaire: A prospective cohort studyResearch in context

Autor: Ronald W. Damant, Liam Rourke, Ying Cui, Grace Y. Lam, Maeve P. Smith, Desi P. Fuhr, Jaqueline K. Tay, Rhea A. Varughese, Cheryl R. Laratta, Angela Lau, Eric Y. Wong, Michael K. Stickland, Giovanni Ferrara

Publikováno v: EClinicalMedicine, Vol 55, Iss , Pp 101755- (2023)

Summary: Background: Many of the 10–20% percent of COVID-19 survivors who develop Post COVID-19 Condition (PCC, or Long COVID) describe experiences suggestive of stigmatization, a known social determinant of health. Our objective was to develop an

Externí odkaz: https://doaj.org/article/5323aeee97a242a6803870fcddf42b42

Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection

Autor: Erkki Lathouwers, Sareh Seyedkazemi, Donghan Luo, Kimberley Brown, Sandra De Meyer, Eric Y. Wong

Publikováno v: HIV Research & Clinical Practice, Vol 21, Iss 2-3, Pp 83-89 (2020)

Background The efficacy and high barrier to resistance of darunavir have been demonstrated across diverse populations with HIV-1 infection. Objective To evaluate post-baseline resistance among patients in studies of once-daily (QD) darunavir-based re

Externí odkaz: https://doaj.org/article/c59070e583c6421891f8058776002563

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study

Autor: Bruce Rashbaum, Christoph D. Spinner, Cheryl McDonald, Cristina Mussini, John Jezorwski, Donghan Luo, Erika Van Landuyt, Kimberley Brown, Eric Y. Wong

Publikováno v: HIV Research & Clinical Practice, Vol 20, Iss 1, Pp 24-33 (2019)

Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection. The 48-week efficacy and safety of D/C/F/TAF versus darunavir/c

Externí odkaz: https://doaj.org/article/2398a84fc10a4d59a8c3ed8590f56b34

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

Autor: Kimberley Brown, Edwin DeJesus, Richard E. Nettles, Erkki Lathouwers, Romana Petrovic, Gregory D Huhn, Donghan Luo, Jean-Michel Molina, Eric Y Wong, Joseph J. Eron, Erika Van Landuyt, Chloe Orkin, Pierre-Marie Girard

Publikováno v: AIDS Research and Therapy, Vol 16, Iss 1, Pp 1-11 (2019)
AIDS Research and Therapy
AIDS Research and Therapy, BioMed Central, 2019, 16 (1), pp.23. ⟨10.1186/s12981-019-0235-1⟩

Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once-daily, single-tablet regimen for treatment of HIV-1 infection. The efficacy/safety of switching to D/C/F/TAF versus continuing boosted proteas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c05dc5b3c9c6fb4e5469961227979170
http://link.springer.com/article/10.1186/s12981-019-0235-1

Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection

Autor: Donghan Luo, Sandra De Meyer, Sareh Seyedkazemi, Kimberley Brown, Erkki Lathouwers, Eric Y Wong

The efficacy and high barrier to resistance of darunavir have been demonstrated across diverse populations with HIV-1 infection. To evaluate post-baseline resistance among patients in studies of once-daily (QD) darunavir-based regimens and formulatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e441a3224467f9b9d4f57cc205d7333e